Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Ascendis Pharma A/S
ISIN DK0060615755
|WKN A42ANJ
Market cap (in EUR)
14,648 m
Country
Denmark
Sector
Healthcare
Overview
Description
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark
Financials
Key metrics
| Market capitalisation, EUR | 14,648 m |
| EPS, EUR | 8.11 |
| P/B ratio | 29.7 |
| P/E ratio | 28.6 |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 720 m |
| Net income, EUR | -228 m |
| Profit margin | -31.67% |
What ETF is Ascendis Pharma A/S in?
There are 2 ETFs which contain Ascendis Pharma A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Ascendis Pharma A/S is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 1.10% | Equity United States Health Care Biotech | 64 |
| Amundi Prime Europe UCITS ETF DR (D) | 0.08% | Equity Europe | 251 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.